Allogene Therapeutics

Yahoo Finance • 4 days ago

September 2025's Promising Penny Stocks Revealed

As U.S. markets navigate a rebound with the Nasdaq and S&P 500 rising, investors are keeping a close eye on potential government shutdowns and economic shifts. Amid these broader market movements, penny stocks continue to capture interest... Full story

Yahoo Finance • last month

Allogene Therapeutics Announces Participation in Upcoming Investor Conference

SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimm... Full story

Yahoo Finance • last month

Discover Promising Penny Stocks This August 2025

As of late August 2025, the U.S. stock market has shown resilience, with major indices closing higher despite political uncertainties and upcoming earnings reports from key players like Nvidia. In such a climate, investors often seek oppor... Full story

Yahoo Finance • 2 months ago

Allogene outlines clinical milestones with MRD data readout planned for first half 2026 as portfolio advances

Earnings Call Insights: Allogene Therapeutics (ALLO) Q2 2025 MANAGEMENT VIEW * CEO David D. Chang reported "significant advancement across our portfolio" and highlighted progress in three key programs: cema-cel in large B-cell lymphoma... Full story

Yahoo Finance • 2 months ago

Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update

Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) ALPHA3 Proceeding as a Two-Arm Randomized Trial Comparing Cema-cel After Standard Fludarabine and Cy... Full story

Yahoo Finance • 2 months ago

Here are the major earnings after the close Wednesday

Major earnings expected after the bell on Wednesday include: * Cisco Systems (CSCO [https://seekingalpha.com/symbol/CSCO]) * Coherent Corp. (COHR [https://seekingalpha.com/symbol/COHR]) * Vaxart (OTC:VXRT [https://seekingalpha.com/s... Full story

Yahoo Finance • 2 months ago

S&P Futures Gain as Fed Rate-Cut Bets Firm

September S&P 500 E-Mini futures (ESU25 [https://www.barchart.com/futures/quotes/ESU25]) are trending up +0.24% this morning, extending yesterday’s gains as growing expectations for Federal Reserve interest rate cuts fueled risk-on sentime... Full story

Yahoo Finance • 2 months ago

Allogene Therapeutics Q2 2025 Earnings Preview

* Allogene Therapeutics (NASDAQ:ALLO [https://seekingalpha.com/symbol/ALLO]) is scheduled to announce Q2 earnings results on Wednesday, August 13th, after market close. * The consensus EPS Estimate is -$0.27 [https://seekingalpha.com/s... Full story

Yahoo Finance • 2 months ago

Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update

Conference Call and Webcast Scheduled for August 13, 2025 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pio... Full story

Yahoo Finance • 2 months ago

Allogene stock continues ALPHA3 trial with standard FC regimen after safety event

Investing.com - Allogene Therapeutics (NASDAQ:ALLO), currently trading at $1.15 and down over 26% in the past week, will continue its ALPHA3 study with a standard FC lymphodepletion regimen following a patient death related to its ALLO-647... Full story

Yahoo Finance • 2 months ago

Allogene stock maintains Market Perform rating at Citizens JMP after trial adjustment

Investing.com - Citizens JMP analyst Reni Benjamin reiterated a Market Perform rating on Allogene (NASDAQ:ALLO), whose shares have declined over 26% in the past week, following the company’s announcement of changes to its ALPHA3 study. The... Full story

Yahoo Finance • 4 months ago

Allogene's SWOT analysis: stock outlook amid clinical delays, promising data

Allogene Therapeutics, Inc. (NASDAQ:ALLO), a biopharmaceutical company focused on developing allogeneic chimeric antigen receptor T-cell (AlloCAR T) therapies for cancer, has been navigating a complex landscape of clinical developments and... Full story

Yahoo Finance • 4 months ago

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

Data Highlights Transformative Promise of CAR T in Solid TumorsPhase 1 Trial with ALLO-316 Demonstrated Potential to Provide Meaningful Clinical Benefit in Patients with CD70 TPS ≥ 50% Advanced or Metastatic RCC A Single Dose of ALLO-316... Full story

Yahoo Finance • 4 months ago

SA Asks: Which oncology companies are attractive M&A targets?

[word m and a made with wood building blocks, stock image] Maksim Labkouski Which cancer drug developers are attractive takeover targets? We asked Seeking Alpha analysts BioCGT Investor [https://seekingalpha.com/author/biocgt-investor],... Full story

Yahoo Finance • 4 months ago

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmu... Full story

Yahoo Finance • 4 months ago

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel

SOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmu... Full story

Yahoo Finance • 5 months ago

Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoim... Full story

Yahoo Finance • 6 months ago

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

Designations Follow Recent Investigational New Drug (IND) Application Clearance for the RESOLUTION Basket Study of ALLO-329 in RheumatologyDual CD19/CD70 CAR T Specifically Designed to Enhance Therapeutic Benefit, Expanding Treatment Poten... Full story

Yahoo Finance • 7 months ago

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Momentum Builds Across Programs with Key Data Milestones Expected in 2025Cemacabtagene Ansegedleucel (Cema-Cel): First-Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Ongoing Pivotal Phase 2 ALPHA3 Trial Advancing with Site Activa... Full story

Yahoo Finance • 7 months ago

Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

Conference Call and Webcast Scheduled for March 13, 2025 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pio... Full story